$7.39
5.38% yesterday
Nasdaq, Jul 02, 10:10 pm CET
ISIN
US12674W1099
Symbol
CABA
Sector
Industry

Cabaletta Bio Inc Share price

$7.39
-2.62 26.17% 1M
-14.77 66.65% 6M
-15.31 67.44% YTD
-4.90 39.87% 1Y
-1.04 12.34% 3Y
-2.61 26.10% 5Y
-2.61 26.10% 10Y
Nasdaq, Closing price Tue, Jul 02 2024
-0.42 5.38%
ISIN
US12674W1099
Symbol
CABA
Sector
Industry

Key metrics

Market capitalization $356.76m
Enterprise Value $141.08m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.61
Turnover (TTM) Turnover $0.00
EBIT (operating result TTM) EBIT $-85.74m
Free cash flow (TTM) Free cash flow $-66.05m
Cash position $223.85m
EPS (TTM) EPS $-1.72
P/E ratio expected negative
Short interest 20.23%
Show more

Is Cabaletta Bio Inc a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.

Cabaletta Bio Inc Share analysis

Unlock Scores for Free

Analyst opinions

11 Analysts have issued a Cabaletta Bio Inc forecast:

11x Buy
100%

Analyst opinions

11 Analysts have issued a Cabaletta Bio Inc forecast:

Buy
100%

Financial data from Cabaletta Bio Inc

Assets
Dec '23
244 244
Cash position 241 241
Claims - -
Inventories - -
Other current assets Other current assets Current assets 3.24 3.24
9.16 9.16
Property, plant and equipment 7.45 7.45
Financial assets - -
Intangible assets - -
Other fixed assets Other assets Fixed assets 1.71 1.71
Total assets 254 254
Liabilities
Dec '23
Equity 236 236
17 17
Current liabilities 16 16
Non-current liabilities 1.46 1.46
Total capital 254 254

Figures in millions USD.

Don't miss a thing! We will send you all news about the Cabaletta Bio Inc share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Cabaletta Bio Inc Share News

Neutral
GlobeNewsWire
about 23 hours ago
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Virtual...
Positive
Seeking Alpha
5 days ago
Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies. It's stock price rose >$25 due to positive data produced by a drug with the same MoA as CABA-201, showing remarkable results with many patients experiencing full recoveries. Cabaletta stock has been sinking in 2024 however due to slow progress, manufacturing conc...
Neutral
GlobeNewsWire
19 days ago
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 –
More Cabaletta Bio Inc News

Company profile

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Head office United States
CEO Steven Nichtberger
Employees 103
Founded 2017
Website www.cabalettabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today